Schrödinger and Bristol Myers Squibb sign deal on agentic AI drug discovery

Aug 5, 2026 · Issue 1 · 4 sources, 4 articles

Schrödinger has announced a strategic collaboration and software agreement with Bristol Myers Squibb. The AI co-scientist Bunsen will be deployed in agentic drug discovery.

Who is affected and how

pharmaceuticals

A large drugmaker is deploying an agentic research tool as contracted software, which raises the question of rethinking internal research workflows.

Sources

• Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discoveryinvestor.wedbush.com · Aug 5, 2026
• 2026-08-05 | Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery | NDAQ:SDGR | Press Releasestockhouse.com · Aug 5, 2026 · magyar
• Schrödinger & BMS expand partnership to deploy AI for drug discoverypharmaceutical technology · Aug 6, 2026
• Schrödinger and BMS expand partnership to deploy AI for drug discoverypharmaceutical-technology.com · Aug 6, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.